Retraction Notice: This article has been officially retracted by the journal Translational Psychiatry. While the following summary reflects the original claims, the data and conclusions should be treated as potentially unreliable in a scientific context.
Abstract
Fluoxetine is a commonly prescribed antidepressant, but the mechanisms behind increased bone fragility with its long-term use remain largely unknown. This study demonstrates that long-term administration of fluoxetine induces the disruption of sphingolipid metabolism in bone marrow adipose tissue (BMAT) through the inhibition of acid sphingomyelinase (ASM). Inhibition of ASM reduces sphingosine-1-phosphate (S1P) levels, leading to increased RANKL secretion and subsequent bone loss. Oral supplementation of L-serine, a sphingolipid precursor, was found to mitigate these effects in a clinical trial of postmenopausal women.
Introduction
Selective serotonin reuptake inhibitors (SSRIs), particularly fluoxetine, are the frontline treatment for major depressive disorder (MDD). However, clinical evidence has long associated chronic SSRI use with increased bone fragility and fracture risk, particularly in vulnerable populations like postmenopausal women. While previous research focused on direct serotonin signaling in bone cells, this study investigates the role of Bone Marrow Adipose Tissue (BMAT) as a metabolic regulator of bone health.
The ASM-S1P Signaling Pathway
The researchers identified that fluoxetine acts as a functional inhibitor of acid sphingomyelinase (ASM) within bone marrow adipocytes. This inhibition disrupts the sphingolipid rheostat, specifically leading to a significant reduction in sphingosine-1-phosphate (S1P).
The drop in S1P levels triggers a downstream signaling cascade:
- Upregulation of the COX-2/PGE2 pathway.
- Increased secretion of RANKL (receptor activator of nuclear factor-kappa-Β ligand).
- Activation of osteoclastogenesis, where bone-resorbing cells are over-stimulated, leading to accelerated bone loss.
Experimental Evidence from Animal Models
To validate this mechanism, the study utilized various animal models, including ASM knockout ($Smpd1^{-/-}$) mice and rat models of menopause (ovariectomized) and depression (chronic unpredictable mild stress). The results consistently showed that both the absence of ASM and the administration of fluoxetine led to significant reductions in bone mineral density (BMD).
As shown in Figure 6, the combination of menopause, stress, and fluoxetine treatment (OVX-CUMS-Flx) resulted in the lowest BMD levels compared to control groups, highlighting the drug's impact on bone health in a complex physiological environment.
Clinical Trial: L-Serine as a Protective Agent
Given that L-serine is a precursor for sphingolipid biosynthesis, the authors hypothesized that supplementation could bypass the fluoxetine-induced metabolic block. They conducted a 12-month randomized, placebo-controlled trial involving 40 postmenopausal women with MDD.
The baseline characteristics (Figure 5) show that the groups were well-matched for age, BMI, and initial BMD. Over the 12-month period, the group receiving fluoxetine plus a placebo experienced a 2.0% reduction in total hip BMD. In contrast, the group supplemented with L-serine (250 mg/kg/day) saw a significantly smaller reduction of only 1.1% ($P = 0.006$), suggesting a protective effect.
Conclusion and Limitations
This study proposes a novel metabolic link between antidepressant use and bone health, identifying BMAT as a key player. However, several critical limitations must be noted. Most importantly, the article has been retracted, casting significant doubt on the validity of the reported data. Additionally, the clinical trial's small sample size ($N=40$) and the focus on a single SSRI limit the broader applicability of these findings. Further independent research is required to confirm whether sphingolipid-targeting therapies can safely mitigate the skeletal side effects of long-term antidepressant therapy.
Summary updated